Can tirzepatide cause depression?

This site's tirzepatide citation findings do not report depression as a measured primary outcome. The record they hold covers weight (SURMOUNT-1: 2,539 adults, up to 20.9% mean weight loss at 72 weeks on 15 milligrams), glycemic head to head (SURPASS-2: 1,879 people over 40 weeks), cardiovascular events (SURPASS-CVOT: 13,299 people; primary MACE 12.2% versus 13.1% on dulaglutide), and sleep apnea (SURMOUNT-OSA at 52 weeks). A mood question is a clinical one for a prescriber. This FAQ does not invent a depression rate from silence.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of more absences and national fields. Further harvested questions after the first names-and-absences set: more side effects the citations did not count, compounding formulas this catalogue does not hold, national legal-status fields for compounds that only have those four countries, trial windows rather than an onset clock, and named prescription combinations with no interaction table.